Sponsors (6)
The bill strengthens allied biodefense coordination and biosurveillance to reduce biological risks, but does so at the cost of tighter controls, possible research impediments, potential gaps from narrowly defined threat scopes, and additional funding burdens.
U.S. diplomats and allied militaries (NATO and partners) will coordinate to strengthen biodefense planning, improving detection, response, and recovery capabilities for biological incidents.
Hospitals, public health systems, and researchers will gain improved biosurveillance and cross-border coordination that can enable earlier detection of outbreaks across human, animal, plant, and environmental health domains.
Scientists, health systems, and partner countries will see promoted adoption of higher biosafety and biosecurity standards among allies, lowering the chance of accidental releases and strengthening pandemic prevention.
Scientists and research labs could face slower legitimate research, added compliance burdens, and higher operating costs due to tighter export controls and coordinated restrictions on sensitive biotech tools.
State and local public health authorities and hospitals could be left exposed if strategies focus narrowly on threats defined under 18 U.S.C. §178, leaving gaps for broader biological risks not covered by that statute.
International scientific collaboration and data sharing could be complicated for researchers and foreign partners by stronger export controls and coordination, hindering joint research and timely information exchange.
Based on analysis of 2 sections of legislative text.
Directs the Secretary of State to deepen allied cooperation on biodefense, produce two strategies, and assess export‑control coordination for sensitive biotechnology items.
Introduced February 23, 2026 by Keith Self · Last progress February 23, 2026
Directs the Secretary of State to strengthen U.S. cooperation with NATO and other allies on biodefense, biosecurity, and biotechnology. It requires active engagement to boost NATO planning, detection, attribution, emergency response, resilience, and consideration of expanded NATO biotechnology capabilities. Requires the State Department to produce two named strategies: a NATO Biodefense Strategy that assesses gaps and U.S.–NATO cooperation, and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy that outlines commitments with allies and evaluates coordinating export controls for risky biotechnology items; it does not appropriate new funds.